Alza wooing biotech clients
Executive Summary
J&J's proposed acquisition of Alza has the potential to attract biotechs to contract for Alza's drug delivery technology, firm says. Younger biotech companies in discussions with Alza view the J&J deal as a positive, Alza maintains